- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | GGT-001, Pulmonary Arterial Hypertension AAV Gene Therapy | ||||||
| Gene Therapy | Pulmonary hypertension | FGF12 | Lead | GluGene Therapeutics | RS-2023-00217737 | ||
| 2 | Project Cell penetrating miRNA-based therapy for acute myocardial infarction | ||||||
| Gene Therapy | Acute heart failure | miRNA (miR-A, 128-3p, 34a-5p, B, 203a-3p) | Candidate | StemMeditech Inc. | HN21C0741 | ||